Company Gentian Diagnostics

Equities

GENT

NO0010748866

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Gentian Diagnostics

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-19 am EDT			5-day change	1st Jan Change
36.6 ^NOK	+1.67%		+1.10%	-11.81%

Mar. 21	Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024	CI
Mar. 21	Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024	CI

Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company's product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Number of employees: 58

NOK in Million	2022	Weight	2023	Weight	Delta
Renal Diagnostic 41.7 %	40	39.3 %	56	41.7 %	+40.92%
Inflammation Diagnostic 38.3 %	43	42.2 %	52	38.3 %	+20.72%
Other Diagnostic 20.0 %	19	18.5 %	27	20.0 %	+44.07%

NOK in Million	2022	Weight	2023	Weight	Delta
Europe 68.6 %	72	70.4 %	93	68.6 %	+29.60%
Asia 24.9 %	24	23.2 %	34	24.9 %	+42.63%
United States 6.5 %	6	6.4 %	9	6.5 %	+35.10%

Managers	Title	Age	Since
Hilja Ibert CEO	Chief Executive Officer	-	18-07-15
Njaal Kind DFI	Director of Finance/CFO	52	18-01-01
Aleksandra Havelka CTO	Chief Tech/Sci/R&D Officer	-	-
Torsten Knüttel CTO	Chief Tech/Sci/R&D Officer	-	19-08-04
Anne-Mette Horsrud Akre LAW	General Counsel	-	-
Markus Jaquemar PRN	Corporate Officer/Principal	-	-
Jack Andreassen PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Thomas Settevik CHM	Chairman	64	-
Fredrik Thoresen BRD	Director/Board Member	44	-
Kari Eian Krogstad BRD	Director/Board Member	60	-
Kjersti Grimsrud BRD	Director/Board Member	63	-
Espen Tidemann Jørgensen BRD	Director/Board Member	49	13-08-31
Monika Neuman BRD	Director/Board Member	59	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	15,422,350	8,458,743 ( 54.85 %)	0	54.85 %

Name	Equities	%	Valuation
Vatne Capital AS 15.11 %	2,330,224	15.11 %	8 M kr
Andenaes Family 10.53 %	1,623,368	10.53 %	6 M kr
Storebrand Asset Management AS 9.513 %	1,467,057	9.513 %	5 M kr
Holta Invest AS (Private Equity) 7.966 %	1,228,502	7.966 %	4 M kr
Bendik Sundrehagen 4.861 %	749,700	4.861 %	3 M kr
John Afseth 3.486 %	537,589	3.486 %	2 M kr
Rasmussen Family 3.469 %	535,000	3.469 %	2 M kr
Norron AB 2.879 %	444,037	2.879 %	2 M kr
DNB Asset Management AS 2.343 %	361,291	2.343 %	1 M kr
Johan Henrik Krefting 1.533 %	236,500	1.533 %	850 494 kr

Gentian Diagnostics ASA

Bjørnåsveien 5

1596, Moss

+47 99 33 99 05

http://www.gentian.no

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36 NOK

Average target price

54 NOK

Spread / Average Target

+50.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
GENTIAN DIAGNOSTICS	-13.25%	50.38M
BIOMÉRIEUX	-2.44%	12.47B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.62%	6.99B
DIASORIN S.P.A.	-4.25%	5.1B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.68%	4.27B
LANTHEUS HOLDINGS, INC.	+0.53%	4.27B
10X GENOMICS, INC.	-48.27%	3.45B
ANDON HEALTH CO., LTD.	+7.09%	2.61B
VITROLIFE AB	-13.87%	2.08B
MYRIAD GENETICS, INC.	-3.40%	1.67B

Diagnostic & Testing Substances